NASDAQ:ITOS

iTeos Therapeutics Competitors

$27.01

-2.99 (-9.97 %)

(As of 04/9/2021 12:00 AM ET)

Add

Compare

Today's Range

$26.70

Now: $27.01▼

$29.99

50-Day Range

$30.00

MA: $37.18▼

$44.20

52-Week Range

$17.50

Now: $27.01▼

$47.61

Volume507,400 shs

Average Volume281,797 shs

Market Capitalization$948.02 million

P/E RatioN/A

Dividend YieldN/A

BetaN/A

iTeos Therapeutics (NASDAQ:ITOS) Vs. SEER, NUVB, IBRX, BCAB, IMCR, and CGEM

Should you be buying ITOS stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to iTeos Therapeutics, including Seer (SEER), Nuvation Bio (NUVB), ImmunityBio (IBRX), BioAtla (BCAB), Immunocore (IMCR), and Cullinan Oncology (CGEM).

iTeos Therapeutics vs. Seer Stock

iTeos Therapeutics (NASDAQ:ITOS) and Seer (NASDAQ:SEER) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, dividends, earnings, risk, analyst recommendations, valuation and institutional ownership.

Insider and Institutional Ownership

71.1% of iTeos Therapeutics shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares iTeos Therapeutics and Seer's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
iTeos Therapeutics	N/A	N/A	N/A
Seer	N/A	N/A	N/A

Analyst Ratings

This is a summary of current recommendations and price targets for iTeos Therapeutics and Seer, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iTeos Therapeutics	0	0	5	0	3.00
Seer	0	2	2	0	2.50

iTeos Therapeutics currently has a consensus price target of $49.40, indicating a potential upside of 82.90%. Seer has a consensus price target of $68.00, indicating a potential upside of 30.79%. Given iTeos Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe iTeos Therapeutics is more favorable than Seer.

Valuation and Earnings

This table compares iTeos Therapeutics and Seer's top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iTeos Therapeutics	N/A	N/A	N/A	N/A	N/A
Seer	N/A	N/A	N/A	N/A	N/A

Summary

iTeos Therapeutics beats Seer on 4 of the 4 factors compared between the two stocks.

iTeos Therapeutics vs. Nuvation Bio Stock

iTeos Therapeutics (NASDAQ:ITOS) and Nuvation Bio (NYSE:NUVB) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, dividends, earnings, risk, analyst recommendations, valuation and institutional ownership.

Insider and Institutional Ownership

Profitability

This table compares iTeos Therapeutics and Nuvation Bio's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
iTeos Therapeutics	N/A	N/A	N/A
Nuvation Bio	N/A	N/A	N/A

Analyst Ratings

This is a summary of current recommendations and price targets for iTeos Therapeutics and Nuvation Bio, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iTeos Therapeutics	0	0	5	0	3.00
Nuvation Bio	0	0	6	0	3.00

iTeos Therapeutics currently has a consensus price target of $49.40, indicating a potential upside of 82.90%. Nuvation Bio has a consensus price target of $17.40, indicating a potential upside of 74.00%. Given iTeos Therapeutics' higher probable upside, analysts plainly believe iTeos Therapeutics is more favorable than Nuvation Bio.

Valuation and Earnings

This table compares iTeos Therapeutics and Nuvation Bio's top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iTeos Therapeutics	N/A	N/A	N/A	N/A	N/A
Nuvation Bio	N/A	N/A	N/A	N/A	N/A

Summary

iTeos Therapeutics beats Nuvation Bio on 2 of the 3 factors compared between the two stocks.

iTeos Therapeutics vs. ImmunityBio Stock

iTeos Therapeutics (NASDAQ:ITOS) and ImmunityBio (NASDAQ:IBRX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, dividends, earnings, risk, analyst recommendations, valuation and institutional ownership.

Insider and Institutional Ownership

Profitability

This table compares iTeos Therapeutics and ImmunityBio's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
iTeos Therapeutics	N/A	N/A	N/A
ImmunityBio	N/A	N/A	N/A

Analyst Ratings

This is a summary of current recommendations and price targets for iTeos Therapeutics and ImmunityBio, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iTeos Therapeutics	0	0	5	0	3.00
ImmunityBio	0	0	1	0	3.00

iTeos Therapeutics currently has a consensus price target of $49.40, indicating a potential upside of 82.90%. ImmunityBio has a consensus price target of $25.00, indicating a potential upside of 48.19%. Given iTeos Therapeutics' higher probable upside, analysts plainly believe iTeos Therapeutics is more favorable than ImmunityBio.

Valuation and Earnings

This table compares iTeos Therapeutics and ImmunityBio's top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iTeos Therapeutics	N/A	N/A	N/A	N/A	N/A
ImmunityBio	N/A	N/A	N/A	N/A	N/A

Summary

iTeos Therapeutics beats ImmunityBio on 3 of the 3 factors compared between the two stocks.

iTeos Therapeutics vs. BioAtla Stock

iTeos Therapeutics (NASDAQ:ITOS) and BioAtla (NASDAQ:BCAB) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, dividends, earnings, risk, analyst recommendations, valuation and institutional ownership.

Insider and Institutional Ownership

Profitability

This table compares iTeos Therapeutics and BioAtla's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
iTeos Therapeutics	N/A	N/A	N/A
BioAtla	N/A	N/A	N/A

Analyst Ratings

This is a summary of current recommendations and price targets for iTeos Therapeutics and BioAtla, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iTeos Therapeutics	0	0	5	0	3.00
BioAtla	0	0	4	0	3.00

iTeos Therapeutics currently has a consensus price target of $49.40, indicating a potential upside of 82.90%. BioAtla has a consensus price target of $58.00, indicating a potential upside of 22.49%. Given iTeos Therapeutics' higher probable upside, analysts plainly believe iTeos Therapeutics is more favorable than BioAtla.

Valuation and Earnings

This table compares iTeos Therapeutics and BioAtla's top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iTeos Therapeutics	N/A	N/A	N/A	N/A	N/A
BioAtla	N/A	N/A	N/A	N/A	N/A

Summary

iTeos Therapeutics beats BioAtla on 3 of the 3 factors compared between the two stocks.

iTeos Therapeutics vs. Immunocore Stock

iTeos Therapeutics (NASDAQ:ITOS) and Immunocore (NASDAQ:IMCR) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, dividends, earnings, risk, analyst recommendations, valuation and institutional ownership.

Profitability

This table compares iTeos Therapeutics and Immunocore's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
iTeos Therapeutics	N/A	N/A	N/A
Immunocore	N/A	N/A	N/A

Insider and Institutional Ownership

Valuation and Earnings

This table compares iTeos Therapeutics and Immunocore's top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iTeos Therapeutics	N/A	N/A	N/A	N/A	N/A
Immunocore	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

This is a summary of current recommendations and price targets for iTeos Therapeutics and Immunocore, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iTeos Therapeutics	0	0	5	0	3.00
Immunocore	0	1	2	0	2.67

iTeos Therapeutics currently has a consensus price target of $49.40, indicating a potential upside of 82.90%. Immunocore has a consensus price target of $54.3333, indicating a potential upside of 53.18%. Given iTeos Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe iTeos Therapeutics is more favorable than Immunocore.

Summary

iTeos Therapeutics beats Immunocore on 4 of the 4 factors compared between the two stocks.

iTeos Therapeutics vs. Cullinan Oncology Stock

iTeos Therapeutics (NASDAQ:ITOS) and Cullinan Oncology (NASDAQ:CGEM) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, valuation, risk, earnings, dividends, analyst recommendations and institutional ownership.

Profitability

This table compares iTeos Therapeutics and Cullinan Oncology's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
iTeos Therapeutics	N/A	N/A	N/A
Cullinan Oncology	N/A	N/A	N/A

Insider & Institutional Ownership

71.1% of iTeos Therapeutics shares are held by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Earnings & Valuation

This table compares iTeos Therapeutics and Cullinan Oncology's top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iTeos Therapeutics	N/A	N/A	N/A	N/A	N/A
Cullinan Oncology	N/A	N/A	N/A	N/A	N/A

Analyst Recommendations

This is a summary of current ratings and target prices for iTeos Therapeutics and Cullinan Oncology, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iTeos Therapeutics	0	0	5	0	3.00
Cullinan Oncology	0	1	3	0	2.75

iTeos Therapeutics currently has a consensus target price of $49.40, indicating a potential upside of 82.90%. Cullinan Oncology has a consensus target price of $48.25, indicating a potential upside of 49.38%. Given iTeos Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe iTeos Therapeutics is more favorable than Cullinan Oncology.

Summary

iTeos Therapeutics beats Cullinan Oncology on 4 of the 4 factors compared between the two stocks.